Phase I trials have commenced for all siRNA anticancer nanotherapeutics: Phase I trials of CALAA-01 and DCR-MYC on patients with solid tumor, multiple myeloma and myeloma were terminated due to dose-limiting toxicities and sponsor decisions. The gene discussed is MYC; the disease is plasma cell myeloma.